Biomagnetics updates prototype bench top version of IOBS biosensor

NewsGuard 100/100 Score

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP - News) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced that an updated prototype bench top version of the Integrated Optical Biosensor ("IOBS") , originally developed at Los Alamos for research purposes, is now complete. Along with the updated instrument an entirely new software interface to operate it has been successfully coded and integrated. The new instrument is currently being validated for performance using well characterized biological assays. This is a significant milestone in the cooperative research agreement that was signed between Los Alamos National Laboratory and Biomagnetics, representing a major step in the development of a new point-of-care diagnostic system.

“We are very excited about the progress being made at the Laboratory, especially the assembly of the bench top version of the integrated optical biosensor”

"We are very excited about the progress being made at the Laboratory, especially the assembly of the bench top version of the integrated optical biosensor," commented Clayton Hardman, CEO of Biomagnetics Diagnostics Corp. He continued, "Now, we will be able to evaluate the assays on this instrument and eventually, start testing human samples for tuberculosis."

Source:

Biomagnetics Diagnostics Corp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global HIV epidemic cannot be ended without keeping former prisoners, other patients engaged in care